We have come a long way to get to this point, with many twists and unexpected turns. A voyage which we have been fortunate to navigate alongside many other expert teams, investigators at biotech and p...
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Lumina...
XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...
The WHO Guideline Development Group decided to recomment dolutegravir as the preferred first-line and second-line treatment for all populations, in contrast with initial studies.